Genomic sequencing Examination of 733 HER2-amplified Major and metastatic breast tumours disclosed sizeable enrichment of mutations that activate RAS–MAPK signalling in Superior tumours taken care of with prior anti-HER2 therapies121. These mutations, together with NF1 and HER2 activating mutations, contribute to resistance to tucatinib and nerat